Alyeska Investment Group
AXDX

Alyeska Investment Group’s Accelerate Diagnostics AXDX Stock Holding History

Alyeska Investment Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-80,547
Closed -$79.7K – 569
2024
Q1 		$79.7K Buy
+80,547
New +$127K ﹤0.01% 444
2023
Q4 		– Sell
-123,898
Closed -$712K – 523
2023
Q3 		$712K Sell
123,898
-1
-0% -$7 ﹤0.01% 434
2023
Q2 		$1M Hold
123,899
– – 0.01% 453
2023
Q1 		$867K Hold
123,899
– – 0.01% 398
2022
Q4 		$875K Sell
123,899
-49,822
-29% -$544K 0.01% 354
2022
Q3 		$2.64M Buy
+173,721
New +$2.88M 0.03% 306
2016
Q3 		– Sell
-15,718
Closed -$2.26M – 455
2016
Q2 		$2.26M Buy
15,718
+319
+2% +$42.8K 0.02% 359
2016
Q1 		$2.21M Buy
15,399
+2,899
+23% +$409K 0.02% 322
2015
Q4 		$2.69M Buy
+12,500
New +$2.28M 0.03% 286

Other funds holding AXDX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CS
Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alyeska Investment Group's AXDX Position: Q2 2024 in Review

Alyeska Investment Group sold out of Accelerate Diagnostics (AXDX) in Q2 2024, closing a stake of 80,547 shares — an estimated $79.7K sold.

Alyeska Investment Group first reported a position in AXDX in Q4 2015 and held it in 9 quarters. The position peaked at $2.69M in Q4 2015. 41 funds tracked by Wall St. Rank hold AXDX as of Q2 2024.

  • Alyeska Investment Group reported no remaining Accelerate Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 80,547 Accelerate Diagnostics shares in Q2 2024, an estimated $79.7K.
  • Alyeska Investment Group first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 9 quarters.
  • Alyeska Investment Group's Accelerate Diagnostics position peaked at $2.69M in Q4 2015.
  • 41 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2024.

Based on Alyeska Investment Group's 13F filing for Q2 2024, filed 14 Aug 2024.